[Federal Register: August 22, 2006 (Volume 71, Number 162)]
[Notices]
[Page 48930]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr22au06-57]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Clinical Laboratory Improvement Advisory Committee
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (P.L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the following committee meeting.
Name: Clinical Laboratory Improvement Advisory Committee (CLIAC).
Times and Dates: 8:30 a.m.-5 p.m., September 20, 2006. 8:30 a.m.-3
p.m., September 21, 2006.
Place: Sheraton Midtown Atlanta Hotel at Colony Square, 188 14th
Street, NE., Atlanta, Georgia 30361, Telephone: (404) 892-6000.
Status: Open to the public, limited only by the space available.
The meeting room accommodates approximately 100 people.
Purpose: This Committee is charged with providing scientific and
technical advice and guidance to the Secretary of Health and Human
Services, the Assistant Secretary for Health, and the Director, CDC,
regarding the need for, and the nature of, revisions to the standards
under which clinical laboratories are regulated; the impact on medical
and laboratory practice of proposed revisions to the standards; and the
modification of the standards to accommodate technological advances.
Matters To Be Discussed: The agenda will include updates from the
CDC, the Centers for Medicare & Medicaid Services, and the Food and
Drug Administration; and presentations and discussion concerning the
future of health laboratory practice including future directions in
laboratory technology, interfaces between the laboratory and
clinicians, and the future of the laboratory workforce. Agenda items
are subject to change as priorities dictate.
Providing Oral or Written Comments: It is the policy of CLIAC to
accept written public comments and provide a brief period for oral
public comments whenever possible. Oral Comments: In general, each
individual or group requesting to make an oral presentation will be
limited to a total time of five minutes (unless otherwise indicated).
Speakers must also submit their comments in writing for inclusion in
the meeting's Summary Report. To assure adequate time is scheduled for
public comments, individuals or groups planning to make an oral
presentation should, when possible, notify the contact person below at
least one week prior to the meeting date. Written Comments: For
individuals or groups unable to attend the meeting, CLIAC accepts
written comments until the date of the meeting (unless otherwise
stated). However, the comments should be received at least one week
prior to the meeting date so that the comments may be made available to
the Committee for their consideration and public distribution. Written
comments, one hard copy with original signature, should be provided to
the contact person below. Written comments will be included in the
meeting's Summary Report.
Contact Person for Additional Information: Devery Howerton, Acting
Chief, Laboratory Practice Standards Branch, Division Public Health
Partnerships--Laboratory Systems, National Center for Health Marketing,
Coordinating Center for Health Information and Service, CDC, 1600
Clifton Road, NE., Mailstop G-23, Atlanta, Georgia 30333; telephone
(404) 718-1016; fax (404) 718-1080; or via e-mail at DHowerton@cdc.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register Notices pertaining to
announcements of meetings and other committee management activities,
for CDC and the Agency for Toxic Substances and Disease Registry.
Dated: August 15, 2006.
Alvin Hall,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. E6-13828 Filed 8-21-06; 8:45 am]
BILLING CODE 4163-18-P